Clinical trial · Observational
Discovering Patterns in Experiences of Patients in Esophageal Cancer Clinical Research
Investigating Factors Affecting Clinical Trial Participation Rates in Patients With Esophageal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Participation in clinical trials usually favors a particular demographic group. But there is limited research available to explain what study attributes affect the completion of these specific demographic groups. This study will investigate the safety and efficacy of esophageal cancer treatments. The focus will be on tracking the rates of completion and withdrawal among these individuals. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future esophageal cancer research.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Rate of patients who decide to enroll in a clinical research.
- timeFrame
- 3 months
- measure
- Number of study participants who remain in clinical research until completion.
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient is at least 18 years of age * Diagnosis of esophageal cancer * Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: * Women of childbearing potential without a negative pregnancy test; or women who are lactating. * Has a serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Inability to perform regular electronic reporting
References
Publications (3)
- BACKGROUNDKim HJ, Bains MS. Randomized clinical trials in esophageal cancer. Surg Oncol Clin N Am. 2002 Jan;11(1):89-109, viii. doi: 10.1016/s1055-3207(03)00076-0. PMID 11928803
- BACKGROUNDHarada K, Rogers JE, Iwatsuki M, Yamashita K, Baba H, Ajani JA. Recent advances in treating oesophageal cancer. F1000Res. 2020 Oct 1;9:F1000 Faculty Rev-1189. doi: 10.12688/f1000research.22926.1. eCollection 2020. PMID 33042518
- BACKGROUNDZhou N, Hofstetter WL. Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer. Expert Rev Mol Diagn. 2020 Apr;20(4):401-411. doi: 10.1080/14737159.2020.1731307. Epub 2020 Feb 24. PMID 32067548